Skip to main content
Infilbray™ (venglustat) logo
A young woman who is sitting and painting, overlayed with purple light
A young woman who is sitting and painting, overlayed with purple light

What is the safety profile for Infilbray™ (venglustat)?

What you’ll learn on this page:

  • The warnings and precautions for Infilbray are suicidal ideation and behavior, lens opacification in pediatric patients, and embryofetal toxicity1
  • The most common adverse reactions were diarrhea, splenomegaly, nausea, depression, gastroenteritis, and vomiting1
  • The safety profile from the pivotal study in patients with Gaucher disease type 31

Infilbray safety profile1

Infilbray warnings and precautions



Suicidal ideation and behavior  
Suicidal ideation and behavior have been reported in patients with Gaucher disease type 3 receiving Infilbray and in unapproved populations receiving another oral formulation of venglustat, both with and without a history of psychiatric disorders.



Assess patients’ underlying risk of psychiatric disorders prior to treatment initiation and monitor for depressive symptoms or suicidal thoughts during treatment with Infilbray. Use caution when prescribing Infilbray to patients with a history of psychiatric disorders. Inform patients or caregivers of the potential for behavioral and mood changes and encourage them to seek medical attention for manifestations of suicidal ideation and behavior, new onset or worsening depression, or other mood changes. Consider changing the therapeutic regimen, including possibly discontinuing Infilbray, if such events occur.



Lens opacification in pediatric patients

Lens opacification may occur in pediatric patients treated with Infilbray. In pediatric patients, perform ophthalmological assessment prior to initiation and annually during treatment. Advise pediatric patients and caregivers to report any visual disturbances during treatment.

Embryofetal toxicity

Based on findings from animal studies, Infilbray may cause fetal harm when administered to a pregnant woman. Prior to initiation, verify pregnancy status in females of reproductive potential and advise them of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment and for 11 days after the last dose. 

Infilbray adverse reactions

Adverse reactions in Infilbray-treated adults and pediatric patients aged 12 to <18 years with Gaucher disease type 3 during the 52-week primary analysis period of the pivotal triala

Adverse reactions


Infilbray     
n=21  
n (%)

Imiglucerase    
n=22  
n (%)

Diarrhea

3 (14%)

0

Splenomegaly

3 (14%)

0

Nausea

3 (14%)

1 (5%)

Depression

2 (10%)

0

Gastroenteritis

2 (10%)

0

Vomiting

2 (10%)

1 (5%)

aAdverse reactions occurring at an incidence of ≥10% in Infilbray-treated patients and greater than in imiglucerase-treated patients.

In a placebo-controlled, pooled analysis of safety data from 362 adult patients exposed to another formulation of venglustat in unapproved populations, depression occurred in 7.7% of patients (n=28) who received venglustat 15 mg orally once daily for a median duration of 52 weeks compared to 5.7% of patients (n=19) who received placebo (n=340). Suicidal ideation and behavior events occurred in 1% (n=4) of venglustat-treated patients compared to none in placebo patients.

The adverse reaction profile observed in pediatric patients (aged 12 to <18 years) did not appear to be different from that observed in adults.1

Frequently asked questions

Relevant pages to view:

Indication

INFILBRAY (venglustat) is indicated for the treatment of neurological manifestations of Type 3 Gaucher disease (GD3) in patients weighing at least 15 kg. 

Important Safety Information

Warnings and Precautions:
Suicidal Ideation and Behavior:

Suicidal ideation and behavior have been reported in patients with GD3 receiving INFILBRAY and in unapproved populations receiving another formulation of venglustat, both with and without a history of psychiatric disorders. Assess patients' underlying risk of psychiatric disorders prior to initiation and monitor for depressive symptoms or suicidal thoughts during treatment. Use caution when prescribing to patients with a history of psychiatric disorders. Inform patients or caregivers of the potential for behavioral and mood changes and to seek medical attention for manifestations of suicidal ideation and behavior, new onset or worsening depression, or other mood changes. Consider changing the therapeutic regimen, including possibly discontinuing INFILBRAY, if such events occur.

Lens Opacification in Pediatric Patients:

Lens opacification may occur in pediatric patients treated with INFILBRAY. In pediatric patients, perform ophthalmological assessment prior to initiation and annually during treatment. Advise pediatric patients and caregivers to report any visual disturbances during treatment.

Embryofetal Toxicity:

Based on animal studies, INFILBRAY may cause fetal harm when administered to a pregnant woman. Prior to initiation, verify pregnancy status in females of reproductive potential and advise them of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment and for 11 days after the last dose.

Adverse Reactions:
The most common adverse reactions reported in ≥10% of INFILBRAY-treated GD3 patients aged ≥12 years were diarrhea, splenomegaly, nausea, depression, gastroenteritis, and vomiting.


Drug Interactions:
Strong CYP3A Inhibitors: Avoid concomitant use with INFILBRAY. Strong CYP3A inhibitors increase venglustat exposure, which may increase the risk of adverse reactions. If concomitant use is unavoidable, reduce INFILBRAY dosage.

Strong or Moderate CYP3A Inducers: Avoid concomitant use with INFILBRAY. Strong or moderate CYP3A inducers decrease venglustat exposure, which may result in decreased efficacy. If concomitant use is unavoidable, monitor for reduced effectiveness.

Please see Full Prescribing Information for INFILBRAY.

Indication

Important Safety Information

References: 1. Infilbray (venglustat). Prescribing information. Genzyme Corporation, Cambridge, MA. 2. Tylki-Szymańska A et al. J Inherit Metab Dis. 2010;33(4):339-346. 

©2026 Sanofi. All rights reserved. All trademarks mentioned are the property of the Sanofi group. MAT-US-2608188-v1.0-11/2026. Last updated: November 2026.